Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497

Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patie...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2007-01, Vol.48 (12), p.2397-2402
Main Authors: Kuzel, Timothy M., Li, Shuli, Eklund, John, Foss, Francine, Gascoyne, Randy, Abramson, Neil, Schwerkoske, John F., Weller, Edie, Horning, Sandra J.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
denileukin diftitox
Diphtheria Toxin - adverse effects
Diphtheria Toxin - therapeutic use
Female
Humans
Interleukin-2 - adverse effects
Interleukin-2 - therapeutic use
interleukin-2 receptor
Lymphoma, Non-Hodgkin - drug therapy
Male
Middle Aged
Non-Hodgkins lymphoma
Receptors, Interleukin-2 - analysis
Recombinant Fusion Proteins - adverse effects
Recombinant Fusion Proteins - therapeutic use
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing ≥20% IL-2R (IL-2R+) or
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190701694186